Loading...
•
Sep 30, 2023
Voyager Therapeutics Q3 2023 Earnings Report
Voyager Therapeutics' financial results for Q3 2023 were reported, featuring collaboration revenue of $4.6 million and a net loss of $25.9 million.
Key Takeaways
Voyager Therapeutics reported a net loss of $25.9 million for the third quarter of 2023, with collaboration revenues totaling $4.6 million. The company is advancing its pipeline, including the initiation of GLP toxicology studies for its anti-tau antibody VY-TAU01 and progress in its SOD1 ALS gene therapy program.
GLP toxicology studies initiated for VY-TAU01 anti-tau antibody for Alzheimer’s disease, targeting a 1H 2024 IND filing.
SOD1 ALS gene therapy program is on track for development candidate selection by the end of the year.
Collaboration revenue was $4.6 million for the third quarter of 2023.
Net loss was $25.9 million for the third quarter of 2023.
Revenue by Segment
Forward Guidance
Voyager anticipates its present cash reserves, along with anticipated reimbursements for development expenditures under the Neurocrine collaborations and interest income, will adequately cover its projected operational costs and capital expenditure demands until mid-2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...